141 related articles for article (PubMed ID: 34572014)
1. PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells.
Tufano M; D'Arrigo P; D'Agostino M; Giordano C; Marrone L; Cesaro E; Romano MF; Romano S
Cells; 2021 Sep; 10(9):. PubMed ID: 34572014
[TBL] [Abstract][Full Text] [Related]
2. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
D'Arrigo P; Russo M; Rea A; Tufano M; Guadagno E; Del Basso De Caro ML; Pacelli R; Hausch F; Staibano S; Ilardi G; Parisi S; Romano MF; Romano S
Oncotarget; 2017 Sep; 8(40):68291-68304. PubMed ID: 28978117
[TBL] [Abstract][Full Text] [Related]
3. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
[TBL] [Abstract][Full Text] [Related]
4. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
[TBL] [Abstract][Full Text] [Related]
5. Combining Magnetic Resonance Imaging with Systemic Monocyte Evaluation for the Implementation of GBM Management.
Giordano C; Sabatino G; Romano S; Della Pepa GM; Tufano M; D'Alessandris QG; Cottonaro S; Gessi M; Balducci M; Romano MF; Olivi A; Gaudino S; Colosimo C
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917598
[TBL] [Abstract][Full Text] [Related]
6. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
Troiani T; Giunta EF; Tufano M; Vigorito V; Arrigo P; Argenziano G; Ciardiello F; Romano MF; Romano S
Br J Cancer; 2020 Jun; 122(12):1782-1790. PubMed ID: 32317723
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
8. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
Shu C; Li Q
Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
[TBL] [Abstract][Full Text] [Related]
9. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.
Liu Y; Carlsson R; Ambjørn M; Hasan M; Badn W; Darabi A; Siesjö P; Issazadeh-Navikas S
J Neurosci; 2013 Aug; 33(35):14231-45. PubMed ID: 23986257
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
[TBL] [Abstract][Full Text] [Related]
12. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
Ricklefs FL; Alayo Q; Krenzlin H; Mahmoud AB; Speranza MC; Nakashima H; Hayes JL; Lee K; Balaj L; Passaro C; Rooj AK; Krasemann S; Carter BS; Chen CC; Steed T; Treiber J; Rodig S; Yang K; Nakano I; Lee H; Weissleder R; Breakefield XO; Godlewski J; Westphal M; Lamszus K; Freeman GJ; Bronisz A; Lawler SE; Chiocca EA
Sci Adv; 2018 Mar; 4(3):eaar2766. PubMed ID: 29532035
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression and prognostic impact in glioblastoma.
Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.
Vlahovic G; Fecci PE; Reardon D; Sampson JH
Neuro Oncol; 2015 Aug; 17(8):1043-5. PubMed ID: 25964311
[No Abstract] [Full Text] [Related]
15. Rapid tumor recurrence in a novel murine GBM surgical model is associated with Akt/PD-L1/vimentin signaling.
Liu F; Xu XH; Li CY; Zhang TT; Yin SL; Liu GQ; Hu F; Yu SB; Chen XQ
Biochem Biophys Res Commun; 2021 Sep; 569():1-9. PubMed ID: 34216991
[TBL] [Abstract][Full Text] [Related]
16. The splicing FK506-binding protein-51 isoform plays a role in glioblastoma resistance through programmed cell death ligand-1 expression regulation.
D'Arrigo P; Digregorio M; Romano S; Tufano M; Rea A; Hausch F; Dedobbeleer M; Vigorito V; Russo S; Bauder M; Rogister B; Romano MF
Cell Death Discov; 2019; 5():137. PubMed ID: 31583120
[TBL] [Abstract][Full Text] [Related]
17. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
[TBL] [Abstract][Full Text] [Related]
18. Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Preusser M; Berghoff AS; Wick W; Weller M
Clin Neuropathol; 2015; 34(6):313-21. PubMed ID: 26501438
[TBL] [Abstract][Full Text] [Related]
19. Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme-a retrospective cohort study.
Masood AB; Batool S; Bhatti SN; Ali A; Valko M; Jomova K; Kuca K
Front Immunol; 2023; 14():1202098. PubMed ID: 37529045
[TBL] [Abstract][Full Text] [Related]
20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]